AGP Executive Report

Suicide prevention in primary care: GP surgeries in the UK are rolling out suicide-prevention awareness packs with Zurich Insurance UK, Samaritans and local partners, aiming to help patients find support before a crisis. Pregnancy medication and fertility questions: A Danish study links prenatal Tylenol/paracetamol exposure to smaller ovaries and wombs in daughters, with researchers stressing it doesn’t prove cause and calling for longer follow-up. Surgery case highlights reconstruction limits: Surgeons at Luzerner Kantonsspital report a rare breast-reconstruction situation where the expected latissimus dorsi muscle was absent, forcing a different approach. Mental health and therapy spotlight: Actor Henry Winkler says long-term talk therapy helped him “empty” distressing thoughts and improve his wellbeing. Health system pressure abroad: US hospitals continue to exit Medicare Advantage deals over administrative barriers and reimbursement issues, with 29 systems dropping plans in 2026. Public health and environment: Coverage also points to Europe’s heat becoming a health crisis and ongoing plastics treaty debates tied to human health risks.

Fusion & Industry: Proxima Fusion and Lower Saxony signed an MoU to build Europe’s first large-scale high-temperature superconducting (HTS) tape facility, with about €140m planned through 2029—an enabling step for more compact fusion power systems. Animal Health: France reported rapid spread of “European Shamonda” among dairy cattle, now in 22 departments, with warnings about risks for pregnant animals and miscarriages/birth defects. Cereal Disease & Food Security: Syngenta and Lyon-based Amoéba expanded their biofungicide deal, giving Syngenta exclusive distribution across EU-27 plus the UK, Ukraine and Switzerland to target septoria and yellow rust. Cardiology Tech Funding: Implicity (Paris) raised €35m to scale AI-driven cardiac remote monitoring and improve heart-failure prediction. Nursing Workforce: A Geneva-based evidence brief argues nursing shortages won’t be fixed by recruitment alone; retention depends on working conditions, pay, respect and career growth. Swiss Policy & Health Access: Liechtenstein’s parliament backed an abortion initiative for the first 12 weeks, but the hereditary prince’s veto still blocks it. Clinical Pipeline Watch: Novartis’ del-desiran Phase 3 in myotonic dystrophy type 1 missed its main goal, delaying a potential first approved treatment. Public Health & Safety: The 2026 Ig Nobel ceremony in Zurich highlighted splash-proof urinal design and other quirky research—an odd reminder that health tech can start anywhere.

Reproductive Health: A new study reports that prenatal Tylenol/paracetamol exposure may be linked with smaller ovaries, fewer ovarian follicles, smaller uteruses and lower reproductive hormone levels in baby girls—researchers stress it’s observational and not proof of cause. Clinical Research (Switzerland): University of Geneva scientists say they’ve restored a defective airway protective barrier in cystic fibrosis by correcting abnormal connexin 43 activity, using molecules already in clinical trials elsewhere. Drug Watch (Swiss pharma): Novartis shares slid after its acquired muscle-wasting drug del-desiran missed a key Phase III goal in myotonic dystrophy type 1, adding pressure to its pipeline and deal strategy. Air Quality & Childhood Health (Switzerland): Swiss researchers found genetic COPD risk in children tracks with slower lung growth specifically where air pollution was highest. Public Health & Safety: A Swiss case report describes a sewing needle lodged in the larynx after accidental swallowing, initially mistaken for stroke symptoms—highlighting the need for fast imaging. Wellness & Lifestyle: The Ig Nobel Prizes returned to Zurich, awarding research on the aerodynamics of nose blowing and other odd-but-serious science.

Swiss health & policy: Switzerland’s Federal Office of Sport reports a drop in soldiers’ fitness-test scores since 2006 (74.2 to 70.4), even as self-rated fitness rose (40% to 56%), with officials pointing to overestimation and training that may not match army test skills. Air quality & lung health: A Swiss birth-cohort analysis links higher genetic risk for COPD to slower lung growth by age six only in children exposed to the highest air pollution, underscoring how environment can flip genetic risk. Child respiratory exposure: A European classroom study finds higher levels of common soil bacteria in dust are associated with slightly lower lung function in children, though it doesn’t prove the bacteria cause the effect. Mental health meds: A review in The Lancet finds antidepressants vary widely in physical side effects, including weight and blood-pressure changes—highlighting why doctors should discuss bodily risks up front. Swiss pharma watch: Novartis shares slide after another late-stage setback (del-desiran in myotonic dystrophy), adding pressure after prior trial failures. Rare disease progress (Swiss biotech): Pharvaris reports strong Phase 3 results for deucrictibant prophylaxis in hereditary angioedema, setting up potential marketing applications. Nutrition & care: Fresenius launches “NutriChef,” real-food-based enteral nutrition for medical supervision, including in Switzerland. Digital sovereignty: Switzerland pilots moving 3,000 government devices from Microsoft 365 toward open-source document tools, aiming for broader rollout by end-2027.

Soil Health in Switzerland: Researchers at the University of Zurich and Agroscope used a citizen-science “underwear burial” experiment, placing 2,000 pairs of cotton underwear at about 1,000 Swiss sites for two months to track how active local soil microbes are. Food Safety Watch: France reported 81 Salmonella cases linked to contaminated pumpkin seeds, with investigations ongoing and recalls/withdrawals affecting products sold via Grand Frais and other retailers. Parkinson’s Drug Pipeline: WHO says dengue still lacks a specific treatment, while a separate WHO review finds only one dengue drug candidate has reached late-stage trials—highlighting how hard it is to turn targets into therapies. Swiss Health & Care Careers: UNITAR and Empower School of Health ran the first Youth Career Accelerator in Health at the Palais des Nations, connecting participants with Swiss hospitals and pharma/biotech players. Rare Medical Case: Doctors in Lausanne reported a West African green mamba bite in a Swiss patient, leading to neurotoxic symptoms and respiratory failure—rare in Europe, but rising with exotic pet ownership. Public Health & Policy: Switzerland is moving toward a national ban on conversion practices, with lawmakers opening the door to wider restrictions.

Public Health & Safety (Kids on the road): A Swiss survey for the Transport and Environment Association finds 41% of parents of children aged 4–7 think the walk to school is dangerous, with 85% of kids crossing roads where speeds are 50 km/h or higher; the group urges safer footpaths, lower speed limits, better crossings, enforcement, and “walking bus” schemes. Cardiology & Pharma (Novartis setbacks): Novartis faces another blow as its late-stage heart drug pelacarsen lowered lipoprotein(a) risk but failed to reduce heart attacks, strokes, or deaths; the news follows recent trial pauses tied to cell-therapy deaths. Health Tech & Access (Swiss digital identity): Procivis expands EUDI Wallet interoperability by adding France to its issuer/verifier testing environment, supporting cross-border credential use as EU countries race toward end-2026 wallet availability. Cancer Survivorship (Activity patterns): A new study maps how childhood cancer survivors’ physical activity varies across the week, highlighting weekend drops and differences between adolescent and adult survivors—aimed at improving long-term care. Climate & Health (Heat impacts): Coverage links Europe’s extreme heat to wider health and energy risks, noting nuclear plant cutbacks in countries including Switzerland and calling for faster climate and energy transitions. Policy & Care (Assisted dying in the spotlight): UK debate continues around assisted dying legislation, with renewed arguments about safeguards and democratic choice.

Assisted dying debate: France’s new “right to aid in dying” law is hailed as a step forward, but advocates say it’s still too restrictive, with eligibility tied to advanced/terminal illness and unbearable suffering. Early lung health: Swiss-led research at the ERS links higher genetic COPD risk in children to reduced lung function growth by age six—especially when air pollution exposure is high. School air quality: Another ERS study reports that common bacteria in classroom dust (including Streptomyces and Mycobacterium) are associated with reduced lung function in children, raising questions about how schools can be kept healthier. Care access in custody: UN experts warn that a Yemen UN staffer with Crohn’s disease and serious complications is being denied specialist medical care while detained. Digital health rehab: A review finds game-based telerehabilitation for multiple sclerosis appears safe and well tolerated at home, with the most consistent gains in balance and postural control. Swiss policy watch: Switzerland is moving toward a national ban on conversion practices. Public health & climate: UN reporting says the 1.5°C warming goal is now “no longer avoidable,” shifting focus to preparing for impacts.

School Air & Lung Health: New ERS research links bacteria in classroom dust (notably Streptomyces and Mycobacterium) with reduced lung function growth in children, pointing to cleaner school environments as a public-health priority. Early Alzheimer’s Prevention: A UK-led international trial will offer the Swiss-developed drug Trontinemab to people without memory loss but at high risk, using blood tests for the p-tau217 marker to target prevention before symptoms. COPD Risk in Childhood: Swiss birth-cohort data presented at ERS found COPD genetic risk tracks with weaker lung function growth from infancy to age 6—especially in children exposed to higher air pollution. Blood Supply Spotlight: Fresenius Kabi and AABB mark Blood Collectors Week (Sept 6–12) to recognize the staff behind safe, reliable blood collection. Heat as a Health Crisis: Coverage highlights Europe’s extreme heat toll and warns that heat is becoming a persistent medical challenge, not just a seasonal spike. El Niño Weather Watch: The WMO says El Niño is likely to strengthen into 2027, raising risks of extreme drought, flooding, and storms. Swiss Health Tech/Trials: Roivant will present Phase 2 PHocus results for mosliciguat in PH-ILD at ERS Congress (Sept 8).

Alzheimer’s Prevention Trial (Europe/Swiss link): Roche-developed trontinemab (aimed at amyloid plaques) is set to be tested in a unique European trial for people without memory-loss symptoms but at higher risk, with UK sites recruiting about 1,600 adults aged 55–80 and using blood tests for p-tau217 to select participants. Swiss Pharma Deal Watch: Novartis’ reported $2B+ acquisition of London-based Myricx is drawing attention from Australian biotech investors after early-stage backers and super funds received more than $300M from the deal. Hospital Strategy (US, not Switzerland but health-system relevant): WakeMed and Atrium Health announced a strategic combination that would bring WakeMed into Atrium Health while keeping WakeMed as a private nonprofit with local governance. Public Health/Wellness Access (GLP-1 generics): As GLP-1 weight-loss patents begin to expire, generic versions are expanding—potentially improving access in systems like the NHS, though availability and equity concerns remain. Assisted Dying Debate (policy): UK political coverage highlights renewed pressure for “watertight safeguards” as MPs debate assisted dying legislation, with Switzerland referenced via the “fly to Switzerland” accounts in the reporting.

Alzheimer’s Prevention Trial (Roche): A Swiss-made Alzheimer’s antibody, trontinemab (Roche), is set to be tested in a “world first” UK trial for people without memory problems, using a blood test for the p-tau217 marker to identify high-risk participants before dementia starts. Rare Disease Gene Therapy Manufacturing (Switzerland): NewBiologix (Switzerland) and Synastra Biotechnology (Turkey) are partnering to build a stable producer cell line for a Duchenne muscular dystrophy gene therapy program, aiming for scalable, reproducible rAAV manufacturing. Respiratory Trial Tech (Switzerland): Evinova (AI-native clinical development) is teaming up with Lothar Medical to integrate respiratory devices (FeNO, spirometry, oscillometry) into a unified trial platform to improve data-rich respiratory clinical trials. ICU Rehab for Obesity (Europe-wide): A new European guidance paper calls for better rehabilitation approaches for critically ill patients with obesity, highlighting how this growing group is often overlooked in ICU care planning. Swiss Health & Environment: Swissinfo reports drought is causing irreversible damage to Swiss forests, with early leaf loss signaling deep tissue harm and possible tree deaths in coming years. Policy Watch (Switzerland): The Swiss Centre Party is campaigning for the 2027 federal elections, explicitly naming healthcare and intergenerational fairness among its priorities.

Cardiovascular Trial Setback (Swiss pharma): Novartis says its experimental pelacarsen cut lipoprotein(a) levels but failed to reduce major heart attacks and strokes in a late-stage trial, a blow to a key “new frontier” in inherited heart-risk management. LGBTQ+ Rights (Switzerland policy): The Swiss Federal Council backs a nationwide ban on conversion practices, aiming to replace uneven canton rules with one clearer standard; reported survey figures suggest the harmful practice still occurs. Cycling Safety (Swiss-based regulator): The UCI, meeting in Aigle, Switzerland, proposes real-time GPS tracking for riders and vehicles at pro road races after high-profile crashes raised location-and-response concerns. Health Tech/Access (Swiss healthcare): Switzerland’s government is also moving on patient-facing provider comparison tools, aiming to make it easier to find care. Quirky Science in Zurich (public health culture): The Ig Nobel awards held in Switzerland honored studies including cockroach milk, soil health via underwear, and a scientific definition of kissing—odd, but a reminder that research can be playful and public-facing.

Heat & Housing: A Swiss survey after the 2026 heatwave finds 67% back wider air-conditioning installation, but 67% oppose public subsidies for private homes; support is higher among men and higher-income respondents, and many want looser rules for installing systems. Maternal & Baby Health: Switzerland’s Federal Statistical Office reports infant deaths in the first year rose 5.5% (to 274) and stillbirths rose 9.7% (to 363) in 2025, with possible links including advanced maternal age and other individual health risks. Kids’ Mental Health in School: A gfs.bern study of paediatricians says school problems are increasingly driving medical visits; 44% of doctors see school-related issues at least daily, and among older pupils, many report depressive moods, eating disorders, self-harm and suicidal thoughts. Rare Disease Breakthrough: Ionis’ zilganersen (zilganersen) gets FDA approval for Alexander disease, positioning a new disease-modifying option for patients and families. Cardio-Pulmonary Treatment: A trial presented at ESC reports pulmonary artery denervation reduced clinical worsening at 2 years in left-sided pulmonary hypertension with heart failure versus medical therapy alone. Medical Tech & Data Security: Swiss-based Novocure says a cybersecurity incident exposed limited patient and provider contact details, while claiming no access to treatment devices and no operational impact. Public Health Safety: The UCI calls for real-time rider safety tracking across pro road races after the death of cyclist Finlay Tarling. Sustainability & Packaging: SIG’s bag-in-box system earns APR Design® recognition for recyclability, highlighting safer dispensing for liquid products. Health & Wellness Travel: A travel study ranks Switzerland among top destinations for travellers over 60, citing healthcare and age-friendly factors. Quirky Science in Zurich: Ig Nobel prizes return to Zurich, including cockroach milk and nose-blowing research, plus a soil study using buried underwear.

CAR-T Safety Watch (Basel): Novartis paused eight rap-cel cell therapy trials in Switzerland after three patients died from severe immune reactions, while two lymphoma/leukemia trials were unaffected; the company says it’s reviewing cases with independent safety boards and sharing updates with authorities. Swiss Pharma Reshuffle: Novartis also signaled up to 130 job cuts in Basel as it consolidates biologics lab work and ends small-scale biologics production at Kleinbasel, with affected staff supported via job centers and early retirement. Heart Care Breakthrough (Zurich): A European Heart Journal study validated a blood-biomarker scoring system to distinguish broken heart syndrome (Takotsubo) from heart attacks in nearly 90% of patients before catheterization. Public Health & Care: An Alzheimer’s support group story highlights how caregiver groups help families cope with dementia’s changing demands. Swiss Economy & Health Costs: Swiss inflation accelerated to the fastest pace in almost two years, driven by a weaker franc—an issue that can feed into everyday health and living costs. Quirky Science in Switzerland: The Ig Nobel awards returned to Zurich, with the medicine prize going to research on the “proper” way to blow your nose.

Rare Disease & Diagnostics: GENFIT will host a virtual KOL event on Sept 9 in Zurich on non-invasive MASH diagnostics, spotlighting its NIS4® and NIS2+® approach for assessing disease activity and fibrosis. Obesity Drug Pipeline: Roche is paying $190m upfront for rights to a Hanmi UCN2 analog, betting on weight loss that may preserve lean muscle, with first Phase 1 clinical data expected soon. Ophthalmology Tech: Alcon launched UNITY® M, a premium surgical microscope, with rollout starting in the U.S. and Japan and expanding to Europe. Public Health Threat: Africa CDC says the Ebola outbreak in DR Congo has expanded to six provinces and 60 health zones, with 6,206 confirmed cases and 3,009 deaths reported. Climate & Health Risk: The WMO warns El Niño is likely to persist through Feb 2027 and could intensify to very strong levels, raising risks of extreme heat, droughts and floods. Swiss Context: A McKinsey study flags concerns that Switzerland is losing ground as a global business location, citing regulatory complexity, tax environment and infrastructure bottlenecks. Travel & Wellness (Indirect): A Swiss-linked travel retail wellbeing week (Nov 30–Dec 4) highlights growing demand for sleep, stress relief and nutrition services while travelling.

Dental Health: Bleeding gums are a common warning sign of gingivitis from plaque buildup, and experts say gentle brushing with a soft toothbrush plus daily cleaning between teeth matters more than “brushing harder,” with persistent bleeding needing a dental check. Infectious Disease: A measles case was confirmed in an Indiana county health update, with officials stressing measles spreads through the air and that MMR vaccination coverage is key. Public Safety & Mental Health: Swiss police say the suspect in the Aarau rave shooting turned himself in and is suffering from “psychological problems,” after a woman was killed and multiple people were injured. Pharma & Jobs in Switzerland: Novartis plans to discontinue small-volume biologics production at its Kleinbasel site by end-2027, potentially affecting about 130 jobs, as activities shift to Basel campus labs. Neurology Treatment: The EU approved modified-release carbidopa/levodopa (Hopledo/Crexont) for Parkinson’s motor fluctuations, with phased rollout expected to start in October 2026. Workplace Safety Standard: Belco in Bermuda received ISO 45001 certification for occupational health and safety, noting ISO’s Switzerland-based role.

Rare Disease Support: Switzerland plans two new laws to boost help for people living with rare diseases, including funding for specialised care structures and information/advisory services, plus a national rare-disease register targeted for early 2030. Job Cuts in Pharma: Novartis will cut up to 130 jobs in Basel by end-2027 after ending small-scale biologics production in Kleinbasel, with work shifting to the Novartis campus across the Rhine. Cardiac Diagnostics: Researchers in Zurich and Greifswald validated the BioTAK score, a new way to spot Takotsubo syndrome earlier—before catheterisation—using a scoring system based on sex and blood biomarkers. Mental Health & Safety: Swiss police say the Aarau rave shooting was a “rampage” carried out by a lone 43-year-old suspect who turned himself in; prosecutors describe him as having psychological problems. Clinical Research: A trial reported enVast-assisted mechanical thrombectomy reduced infarct size in large-thrombus STEMI patients, adding to the evidence for thrombectomy approaches.